Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“I like the diversity of topics that MedCity News covers – ranging from devices to policy to start-up companies. Always something interesting to find.”

Robert J. Szczerba, Ph.D., CEO, X Tech Ventures


Sign up for our daily newsletter


MedCity morning read, Monday, Feb. 9

8:55 am by | 0 Comments

Procter & Gamble headquarters (courtesy of P&G)

Procter & Gamble headquarters (courtesy of P&G)

Cincinnati consumer products company Procter & Gamble is working with investment bank Goldman Sachs to find buyers for its prescription drug business or ways to exit the business, sources close to the matter told Financial Times last week.

The maker of Gillette razors and Crest toothpaste has been working to focus on high-growth businesses and get out of those that are not core to its consumer products mission, FT said.

P&G’s decision is one of only a few by Ohio companies to contract rather than to grow, even during the recession, said Tony Dennis, president and chief executive of BioOhio, the state’s bioscience company development organization.

That’s the downside to it,” Dennis said last week before leaving for Washington for two days of pitching the Ohio bioscience industry to policy makers. “The upside is, [the decision] will enhance their OTC business. They’re much more skilled with the OTC business, anyway.”

Procter & Gamble sells many over-the-counter remedies, such as Pepto-Bismol (nausea) and Prilosec (heartburn). The company’s prescription drugs have focused on women’s health, and on gastrointestinal and musculoskeletal problems.

The company’s health care division, which includes its pharmaceuticals business, had $14.6 billion in sales and $2.5 billion in net earnings last year, according to Financial Times. P&G told that newspaper that its pharmaceuticals unit accounts for global sales of more than $2 billion.

P&G shares hit a 52-week low of $52.21 on Feb. 2 after the company reported disappointing second-quarter results and lowered its full-year expectations. In December, A.G. Lafley, P&G’s chief executive, told analysts his company had stopped investing in new drug development and would consider selling some of its key drug brands.

Other stories worth a read:

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Mary Vanac

By Mary Vanac

Mary Vanac is a co-founder of MedCity News.
More posts by Author

0 comments